PRESS RELEASE
PRESS RELEASE Ipsen expects Increlex supply interruption due to supplier manufacturing issues
Ipsen and bioMérieux enter into a broad partnership in personalized medicine
PRESS RELEASE Ipsen announces new data to be presented at ASCO in line with its continued commitment to Oncology research
PRESS RELEASE
Ipsen intègre un nouveau programme à son portefeuille R&D de produits d'oncologie en phase pré-clinique grâce à une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la protéine modificatrice d'ARN METTL3 | Business
News articles listing - Ipsen
News articles listing - Ipsen
PRESS RELEASE Oncodesign et Ipsen signent un partenariat stratégique en oncologie et Oncodesign intègre le Campus d'Ipsen à
News articles listing - Ipsen
PRESS RELEASE
ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and in combination across different tumor types includin
Press Releases - Ipsen
Press Releases - Ipsen UK
News articles listing - Ipsen
ESMO 2021: Cabometyx® demonstrates sustained 78% reduction in risk of disease progression or death in people living with uncom-
Ipsen and Marengo Therapeutics announce strategic partnership to advance two precision immuno-oncology candidates from Marengo S
PRESS RELEASE Ipsen announces EMA validation of filing of a new application for additional indication for Cabometyx®, for patie
Press Releases - Ipsen UK
PRESS RELEASE Ipsen announces acceptance of filings for Somatuline in the treatment of GEP-NETs in the US with priority review a
Press Releases - Ipsen UK
Press Releases - Ipsen
Ipsen (@IpsenGroup) / Twitter
Press Releases - Ipsen UK
